Tuesday, July 25, 2023 8:46:56 AM
IRVINE, CA / July 24, 2023 / HippoFi, Inc. (OTCPK:ORHB) a leading healthcare technology company and authority in spinal biologics, focused on the development and distribution of innovative biotech products, is proud to announce that over the last 6 months, while under a confidential Letter of Intent in a strategic partnership, HippoFi has designed and formulated a strategic launch of the PURmarrow 360 bone marrow aspirate (BMA) device throughout the United States.
This product is a natural extension to our robust product line, allowing surgeons to safely and selectively capture the highly desired cells from a patient’s own BMA during surgery. This rich marrow enhances the effectiveness of PUR’s products by combining the stem cells, growth factors, and proteins, helping to supercharge bone growth in spine surgeries and improve patient healing.
“As a market leader in innovation, we believe PURmarrow 360 is in the patient’s best interest, as the purity and genetic makeup of their own living cells is unmatched. PURmarrow 360 is simple to use, without requiring centrifugation, making it easy for spine surgeons to incorporate in every spine surgery.” shared, CJ Wiggins, Executive Chairman and CEO of HippoFi.
To learn more about PUR Biologics' full line of biologic products, visit: www.PURbiologics.com
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM